Farmacy

Jan 9 2018

Exclusive Biotech Research, dendreon pharmaceuticals.#Dendreon #pharmaceuticals

Dendreon pharmaceuticals

Dendreon pharmaceuticals

News Comments

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric

The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect

Important news has come from the FDA, which issued new guidelines to speed the introduction of treatments with human cells and tissues, including gene therapy. Cracking down on rogue clinics offering

Nektar Therapeutics: Speeding Its Flight Towards the Moon

Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s fundamentals from reported finances, to reported products’ results, etc.,

Today s Highlights

In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

ON Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed it that it will respond

Could DelMar Pharmaceuticals Drug VAL-083 ($1 Stock Price) Defeat Glioblastoma Multiforme?

DelMar Pharmaceuticals (DMPI) — A biopharmaceutical company focused on the development of cancer therapies provided an overview of three scientific

Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

Yes, it is Sangamo’s (SGMO), zinc finger nuclease (ZFN) gene-editing technology, which for the first time in history enabled a patient to receive a

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics. (HALO) announced that it will present nonclinical data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer

Recent Popular Posts:

In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

ON Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed it that it will respond to the Prior Approval Supplement (PAS) request to change the current

Could DelMar Pharmaceuticals Drug VAL-083 ($1 Stock Price) Defeat Glioblastoma Multiforme?

DelMar Pharmaceuticals (DMPI) — A biopharmaceutical company focused on the development of cancer therapies provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the





Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *